Gene Expression Profiling for Predicting the Response to Immunotherapy and/or the Survivability of Melanoma Subjects
A method is provided in various embodiments for determining a profile data set for predicting the response top immunotherapy and or survivability of a subject with melanoma based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification under measurement conditions that are substantially repeatable for measuring the amount of RNA corresponding to at least 2, 3 or 4 constituents according to the gene models shown in Tables 2-3, 4-6 and 9.
1 . A method for predicting the survivability of a melanoma-diagnosed subject based on a sample from the subject, the sample providing a source of RNAs, comprising:
a) determining a quantitative measure of the amount of:
i) CTSD, PLA2G7, TXNRD1 and IRAK3;
ii) at least two constituents according to any of the 2-gene models shown in Table 3 or 9;
iii) at least three constituents according to any of the 3-gene models shown in Table 5; or
iv) at least four constituents according to any of the 4-gene models shown in Table 6;
as distinct RNA constituents in the subject sample, wherein such measures are obtained under measurement conditions that are substantially repeatable and the constituents are selected so that measurement of the constituents enables prediction of the survivability or survival time of a melanoma-diagnosed subject; and
b) comparing the quantitative measure of the constituents in the subject sample to a reference value.
2 . The method of claim 1 , wherein at least 4 constituents are measured, and said constituents are CTSD, PLA2G7, TXNRD1 and IRAK3.
3 . The method of claim 1 , wherein said reference value is an index value.
4 . The method of claim 1 , wherein the sample is selected from the group consisting of blood, a blood fraction, a body fluid, cells and tissue.
5 . The method of claim 1 , wherein the measurement conditions that are substantially repeatable are within a degree of repeatability of better than ten percent.
6 . The method of claim 1 , wherein the measurement conditions that are substantially repeatable are within a degree of repeatability of better than five percent.
7 . The method of claim 1 , wherein the measurement conditions that are substantially repeatable are within a degree of repeatability of better than three percent.
8 . The method of claim 1 , wherein efficiencies of amplification for all constituents are substantially similar.
9 . The method of claim 1 , wherein the efficiency of amplification for all constituents is within ten percent.
10 . The method of claim 1 , wherein the efficiency of amplification for all constituents is within five percent.
11 . The method of claim 1 , wherein the efficiency of amplification for all constituents is within three percent.
12 . A kit for predicting the survivability of a melanoma diagnosed subject, comprising at least one reagent for the detection or quantification of any constituent measured according to claim 1 and instructions for using the kit.
13 . A method for predicting the response to immunotherapy and/or survivability of a melanoma-diagnosed subject based on a sample from the subject, the sample providing a source of RNAs, comprising:
a) determining a quantitative measure of the amount of:
i) CTLA4 and ST14 or
ii) LARGE, NFKB1, BAX and TIMP1
as distinct RNA constituents in the subject sample, wherein such measures are obtained under measurement conditions that are substantially repeatable and the constituents are selected so that measurement of the constituents enables prediction of response to therapy and/or the survivability or survival time of a melanoma-diagnosed subject; and
b) comparing the quantitative measure of the constituents in the subject sample to a reference value.
14 . The method of claim 13 , step a) i) further comprising determining a quantitative measure of the amount of IFI16 and ICAM.
15 . The method of claim 13 , step a) i) further comprising determining a quantitative measure of the amount of at least one additional gene selected from the group consisting RBM5, HMGA1 and HLADRA.
16 . The method of claim 13 , wherein said reference value is an index value.
17 . The method of any of claims 13 , wherein the sample is selected from the group consisting of blood, a blood fraction, a body fluid, cells and tissue.
18 . The method of any of claims 13 , wherein the measurement conditions that are substantially repeatable are within a degree of repeatability of better than ten percent.
19 . The method of any of claims 13 wherein the measurement conditions that are substantially repeatable are within a degree of repeatability of better than five percent.
20 . The method of any of claims 13 , wherein the measurement conditions that are substantially repeatable are within a degree of repeatability of better than three percent.
21 . The method of any of claims 13 , wherein efficiencies of amplification for all constituents are substantially similar.
22 . The method of any of claims 13 , wherein the efficiency of amplification for all constituents is within ten percent.
23 . The method of any of claims 13 , wherein the efficiency of amplification for all constituents is within five percent.
24 . The method of any of claims 13 , wherein the efficiency of amplification for all constituents is within three percent.
25 . A kit for predicting the response to immunotherapy and/or survivability of a melanoma diagnosed subject, comprising at least one reagent for the detection or quantification of any constituent measured according to a claim 13 and instructions for using the kit.